Investee Company – Cellectis SA
Investee Company Business Type – Develops technology for genome rewriting
Type of Financing – Expansion
Equity Providers – BankInvest BioMedical Venture, AGF Private Equity, funds managed by LCF Rothschild Asset Management and Odyssee Venture
Equity Leader (Individual) – Martin Bitsch, senior advisor of BankInvest BioMedical Venture
Debt Providers – N/A
Debt Type – N/A
Debt Leader (Individual) – N/A
Equity Amount – euro16 million
Total Deal Value – euro16 million
Other Advisors – N/A
Comments – Cellectis SA has secured a total of euro16 million in second round funding. This financing round was led by BankInvest BioMedical Venture. AGF Private Equity, funds managed by LCF Rothschild Asset Management and Odyssee Venture also participated.
Headquartered in Paris, France, Cellectis SA applies the Meganuclease Recombination Systems (MRS) approach to in vivo genome engineering. The company’s therapeutic development programme involves the use of custom made Meganucleases for the treatment of inherited genetic disease and of viral infectious disease.
;This is an exciting time for Cellectis,” said André Choulika, PhD, Cellectis’ president & CEO. “The infusion of new equity will allow us to significantly expand our in-house programmes for automation of custom made Meganuclease, while also strengthening our collaborative programmes with partners.